10.5 million people in the Arab world’s most medically trusted research destination; King Hussein Cancer Center as the region’s WHO Collaborating Centre, medical tourism drawing cancer patients from across the Arab world, and a USD-pegged dinar eliminating currency risk.
Jordan is a constitutional monarchy of approximately 10.5 million people occupying 89,342 km² of the eastern Levant; a largely arid plateau country at the crossroads of the Arab world, bordered by Syria to the north, Iraq to the northeast, Saudi Arabia to the east and south, and Israel/Palestine to the west along the Jordan River and the shores of the Dead Sea (at ~430m below sea level, the Earth’s lowest point on land). Despite having no oil wealth, Jordan has established itself as the Arab world’s most trusted medical destination; a reputation built on high physician training standards, politically stable governance, and a healthcare infrastructure that relative to income level is among the most sophisticated in the MENA region. Amman; the capital and primate city, with approximately 4 million in the greater metropolitan area; hosts essentially all of Jordan’s clinical research infrastructure: the King Hussein Cancer Center, Jordan University Hospital, the Royal Medical Services’ King Hussein Medical Center, and an established cluster of internationally connected private hospitals. Jordan’s most transformative demographic characteristic for clinical research is the scale of its medical tourism: patients from Iraq, Yemen, Libya, Sudan, Palestine, Syria, Saudi Arabia, Kuwait, and other Arab and African nations travel to Amman for cancer treatment, cardiac surgery, and specialist care unavailable or inadequate in their home countries; creating a patient catchment at Amman’s major hospitals that spans 15+ nationalities and extends Jordan’s effective research reach across the Arabic-speaking world. Jordan also hosts approximately 1.3–1.5 million Syrian refugees; one of the world’s highest per-capita refugee concentrations; creating specific research opportunities in conflict-affected mental health, chronic disease management disruption, and emerging infectious disease that no other stable, research-capable country in the region can replicate.
Clinical trials are regulated by the JFDA (Jordan Food and Drug Administration); one of the Arab world’s most respected pharmaceutical regulatory agencies; under Good Clinical Practice regulations aligned with WHO GCP and ICH GCP E6(R2) standards; JFDA has a bilateral cooperation MOU with the US FDA and is recognised as a pharmaceutical regulatory reference authority among Arab League members. Ethics review is managed through institutional Institutional Review Boards (IRBs) at major research hospitals, with national coordination under the Higher Health Council. JFDA clinical trial approval timelines are typically 2–3 months for standard Phase II–III applications, and the regulatory process is conducted primarily in English; reflecting the predominant language of Jordan’s medical and research community. The Jordanian Dinar (JOD) has been pegged to the US Dollar at approximately 1 JOD = 1.41 USD since 1995; creating zero foreign exchange risk for USD-denominated trial budgets, a financial stability shared in the MENA region with Saudi Arabia and the UAE but at a significantly more cost-competitive operational level. Jordan’s academic medical infrastructure includes four major medical schools whose graduates; many with postgraduate training in the United States, United Kingdom, or Germany; constitute the investigator community for Jordan’s growing Phase II–IV commercial trial portfolio.
Jordan’s population is predominantly Levantine Arab; with a complex demographic history shaped by multiple waves of Palestinian displacement (1948, 1967, and subsequent), Syrian refugee influx (from 2011 onward), and the historical Transjordanian tribal population whose East Bank Jordanian identity defines the kingdom’s political and social core. Approximately 55–60% of Jordanian citizens are of Palestinian origin (including many who hold full Jordanian citizenship), creating a population whose Levantine Arab genetic profile encompasses both the Palestinian-Jordanian ancestral mosaic and the East Bank Bedouin tribal genetic background. Smaller Circassian (~2%) and Chechen (~1%) communities; descendants of 19th-century Caucasian refugees settled by the Ottoman Empire; and a Christian Arab minority (~2–3%, predominantly Greek Orthodox and Roman Catholic) add further ethnic texture. The Syrian refugee population; estimated at 1.3–1.5 million, approximately 12–14% of total Jordan population; is predominantly concentrated in northern Jordan (Irbid and Mafraq governorates, near the Syrian border), in Amman’s urban periphery, and in the Zaatari refugee camp (~80,000 residents, one of the world’s largest) and Azraq camp; the majority of Syrian refugees are in urban settings rather than camps, accessing Jordanian public healthcare through the Ministry of Health system. English proficiency among Jordanian physicians and researchers is very high; reflecting the country’s English-medium university medical education tradition and the significant proportion of Jordanian physicians who trained in English-speaking countries; Arabic is the language of patient care and informed consent. Jordan’s investigator community is notable for its international orientation: a disproportionately high share of Jordanian physician investigators hold postgraduate degrees from US, UK, or European institutions, creating a research culture that bridges Arabic-speaking patient populations with Western GCP-standard trial execution.
Jordan’s disease burden has transitioned rapidly from infectious to non-communicable disease over the past three decades; driven by urbanisation, dietary Westernisation, and sedentary lifestyle changes. Cardiovascular disease is the leading cause of death (~35% of mortality); Type 2 diabetes affects approximately 17–20% of adult Jordanians; among the highest rates in the Arab world, comparable to Gulf countries despite Jordan’s much lower per-capita income; driven by the same dietary transition factors affecting the broader MENA region; obesity affects approximately 38–40% of adults, among the highest rates in the Arab world and globally. Cancer is the second leading cause of death, with breast cancer the most common malignancy in women, colorectal cancer growing rapidly, and haematological malignancies representing a significant burden whose management draws patients from across the Arab world to King Hussein Cancer Center. Mental health disorders; depression, anxiety, and PTSD; carry elevated burden compounded by the psychological impact of hosting one of the world’s largest displaced populations; Jordan’s Ministry of Health and WHO Jordan office have documented elevated mental health disorder rates in both the host community and the Syrian refugee population. Thalassaemia is present in parts of the Jordanian population at rates reflecting Levantine Mediterranean ancestry. Cutaneous leishmaniasis (“Aleppo boil”); historically endemic in Syria; has seen increased transmission in Jordan since the Syrian refugee influx, creating a research platform for the disease in a non-endemic host country context.
King Hussein Cancer Center and Jordan’s medical tourism oncology platform; the Arab world’s multi-country cancer research ecosystem in a single institution: Founded in 1997 and situated on the slopes of Amman’s western hills, King Hussein Cancer Center (KHCC) is the Arab world’s most internationally recognised comprehensive cancer centre; JCI-accredited, a WHO Collaborating Centre for Cancer Control, a member of the Organisation of European Cancer Institutes (OECI), and the recipient of the Arab Health Award for excellence in oncology. KHCC provides the full spectrum of cancer care; radiation oncology, medical oncology, surgical oncology, paediatric oncology, haematological malignancies, bone marrow transplantation, and palliative care; to a patient population that is fundamentally multi-national: in any given clinical period, KHCC’s inpatient and outpatient census includes cancer patients from Iraq, Yemen, Libya, Sudan, Palestine, Syria, Saudi Arabia, Egypt, Algeria, Kuwait, and beyond who have travelled to Amman because KHCC provides cancer care unavailable or inaccessible in their home countries. For clinical trial sponsors, KHCC creates a research environment of extraordinary geographic scope within a single Jordanian JFDA regulatory submission: an oncology Phase II–III trial activated at KHCC has access to a patient population whose Arab ancestral diversity spans North African (Libyan, Sudanese), Levantine (Palestinian, Syrian, Jordanian, Lebanese), Arabian Peninsula (Yemeni), and Mesopotamian (Iraqi) genetic backgrounds simultaneously; multi-country Arabic-speaking oncology enrollment within a single institutional ethics approval and a single regulatory framework. KHCC’s clinical research department manages an active Phase I–IV oncology trial portfolio with established partnerships with MD Anderson Cancer Center, St. Jude Children’s Research Hospital, the European Organisation for Research and Treatment of Cancer (EORTC), and multiple multinational pharmaceutical companies; its investigator community publishes in Lancet Oncology, Journal of Clinical Oncology, Cancer, and other tier-1 journals; and its dedicated research IRB meets GCP standards that international pharmaceutical company auditors consistently rate as among the Arab world’s most rigorous.
Jordan’s research proposition rests on four elements unique in the Arab world: KHCC’s multi-national oncology patient catchment that draws cancer patients from 15+ Arab countries under a single JFDA regulatory filing; a JOD pegged to the USD since 1995 providing zero FX risk at a cost structure far below the Gulf; the Arab world’s most internationally trained physician research community relative to national income; and the specific Syrian refugee population research opportunity; the world’s largest per-capita displaced community still within a functioning healthcare and regulatory jurisdiction.
JFDA (Jordan Food and Drug Administration) regulatory authority aligned with WHO GCP and ICH GCP E6(R2) standards; bilateral MOU with US FDA and cooperation agreement with EMA; JFDA recognised as pharmaceutical regulatory reference authority among Arab League members; institutional IRBs at all major research hospitals meeting international GCP standards; clinical trial approval timelines typically 2–3 months; English-language regulatory submissions standard across JFDA; JOD/USD peg simplifying financial management; Jordan’s political stability; consistently the most stable Levantine state; ensuring regulatory continuity and operational reliability.
Jordanian Dinar pegged to USD at 1 JOD = 1.41 USD since 1995; zero foreign exchange risk for USD-denominated trial budgets; per-patient and operational costs substantially below Gulf countries (Saudi Arabia, UAE) and below Israel; competitive investigator fees, hospital overhead, and CRO services relative to the research quality delivered; English-language medical training environment reducing translation overhead; Amman’s Queen Alia International Airport with direct connections to major European and MENA hubs; compact Amman research cluster reducing internal trial logistics to negligible overhead.
10.5M Jordanian population + KHCC’s multi-national Arab medical tourism catchment (15+ countries) under single JFDA submission; Jordan’s own population among Arab world’s highest T2D (~17–20%) and obesity (~38–40%) rates for metabolic medicine programs; 1.3–1.5M Syrian refugees for mental health, conflict-related NCD, and refugee health research; Levantine Arab pharmacogenomics (Jordanian, Palestinian, Syrian ancestry) for MENA pharmacogenomic reference; thalassaemia present in Mediterranean-ancestry communities; cutaneous leishmaniasis in refugee-affected zones; KHCC haematological malignancy catchment from across the Arab world.
King Hussein Cancer Center (JCI-accredited; WHO Collaborating Centre; OECI member; Arab world reference cancer centre); Jordan University Hospital (UJ; primary public academic medical centre); King Hussein Medical Center / Royal Medical Services (Jordan’s military medical network); Specialty Hospital and Jordan Hospital (Amman private research hospitals); King Abdullah University Hospital / JUST (northern Jordan academic anchor); internationally trained investigator community (high proportion of US/UK/German postgraduate degrees); established IQVIA and ICON presence in Amman; JFDA-approved regulatory pathway navigated by experienced local CRO teams.
Oncology; anchored by KHCC’s Arab-world-spanning patient catchment and internationally connected research programme; is Jordan’s most globally distinctive research pillar. KHCC’s Phase I–IV oncology trial portfolio spans breast cancer (the most common cancer in Jordanian and Arab women), haematological malignancies (lymphoma, leukaemia, myeloma; whose complex treatment requirements specifically drive patients from Iraq, Yemen, and Libya to KHCC for care unavailable at home), paediatric oncology (St. Jude Children’s Research Hospital partnership), colorectal cancer (growing rapidly in Jordan’s westernising diet population), and bone marrow transplantation (one of the Arab world’s most experienced BMT programmes). No other institution in the Arab world provides equivalent oncology research depth combined with a built-in multi-national Arabic-speaking patient pool that is accessible under a single regulatory submission. Metabolic disease; including Jordan’s extraordinary T2D and obesity prevalence rates (among the Arab world’s highest despite a lower income level than Gulf countries); is the second major commercial research pillar, creating large treatment-naïve patient pools for GLP-1, SGLT2, anti-obesity, and NASH programs accessible at a cost structure far below Saudi Arabia’s or the UAE’s. Cardiovascular medicine is Jordan’s third major pillar, anchored by the Royal Medical Services’ King Hussein Medical Center’s cardiac programme and Jordan University Hospital’s internal medicine research tradition. Mental health and refugee health is Jordan’s most globally distinctive emerging research frontier; the Syrian refugee crisis has created the world’s most concentrated and accessible displaced population within a functioning research jurisdiction, and WHO Jordan, UNHCR, IRC, and Jordanian academic institutions have built the research infrastructure to conduct mental health intervention trials, chronic disease management studies, and infectious disease programs in this population. Haematology (thalassaemia in Levantine populations; sickle cell trait in some communities), infectious disease (cutaneous leishmaniasis from Syria border transmission; HCV in older cohorts), women’s health, and paediatric medicine complete a research portfolio whose KHCC oncology anchor and refugee health context create two globally irreplaceable research arguments for a country of 10.5 million.
Amman dominates Jordanian clinical research; the capital metropolitan area of approximately 4 million people contains essentially all major research hospitals, the JFDA regulatory authority, and Jordan’s entire academic medical ecosystem. KHCC occupies a category of its own as the Arab world’s reference cancer institution; the Royal Medical Services’ King Hussein Medical Center provides the Jordan Armed Forces’ comprehensive medical network; and a cluster of internationally connected private hospitals (Specialty Hospital, Jordan Hospital, Islamic Hospital) provide private-sector research access to Jordan’s professional and middle-class patient population. Irbid in the north; home to Jordan University of Science and Technology and proximate to the Syrian refugee concentrations; provides the second research corridor with its own academic teaching hospital.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | King Hussein Cancer Center (KHCC) | Amman | The Arab world’s most internationally recognised comprehensive cancer centre; JCI-accredited, a WHO Collaborating Centre for Cancer Control, and a member of the Organisation of European Cancer Institutes (OECI); offering the full spectrum of oncology services (radiation, medical, surgical, paediatric oncology, bone marrow transplantation, haematological malignancies) to a patient population drawn from 15+ Arab and African countries; Phase I–IV clinical trial portfolio with active partnerships with MD Anderson Cancer Center, St. Jude Children’s Research Hospital, and EORTC; KHCC’s dedicated clinical research department, GCP-compliant IRB, and internationally published investigator community create the Arab world’s most credentialed oncology trial execution environment; the multi-national medical tourism patient catchment makes KHCC the only institution in the Arab world where a Phase II–III oncology trial simultaneously accesses Jordanian, Iraqi, Yemeni, Libyan, Palestinian, Syrian, and North African Arabic-speaking cancer patients within a single regulatory submission. |
| 02 | Jordan University Hospital (JUH) | Amman | Jordan’s primary public academic medical centre; affiliated with the University of Jordan (UJ) School of Medicine, the country’s oldest and largest medical school; and a significant Phase II–IV commercial research site across internal medicine, cardiovascular, endocrinology (Type 2 diabetes), oncology, nephrology, and neurology; Jordan University Hospital’s academic connection to UJ’s medical school produces the national investigator pipeline for Jordan’s public hospital research network and maintains active international academic partnerships through which multinational Phase II–III commercial programmes activate Jordanian sites; its large public hospital patient catchment; serving Amman’s diverse urban and suburban population including significant Palestinian-origin and Syrian refugee communities; creates research access to the Levantine Arab demographic breadth that defines Jordan’s urban patient profile. |
| 03 | King Hussein Medical Center (Royal Medical Services) | Amman | The flagship hospital of Jordan’s Royal Medical Services (RMS); the Armed Forces’ comprehensive healthcare network serving military personnel, veterans, and their families across Jordan; and one of the Kingdom’s most research-active tertiary institutions; Phase II–IV commercial trial activity across cardiovascular (one of Jordan’s most active cardiac surgery and interventional cardiology programmes), oncology, haematology, internal medicine, and emergency medicine; King Hussein Medical Center’s RMS affiliation provides structured patient access to Jordan’s large military and veterans community; a population with distinct demographic characteristics and healthcare engagement patterns complementary to the civilian hospital networks; and its comprehensive cardiac programme makes it a key site for cardiovascular Phase II–III programs requiring Jordanian military and civilian patient coverage. |
| 04 | Specialty Hospital | Amman | One of Amman’s most internationally connected and research-active private hospitals; a major medical tourism destination in its own right, attracting patients from Gulf countries, Iraq, Libya, and Yemen for specialist care; with Phase II–IV commercial trial activity across oncology, cardiovascular, neurology, and internal medicine; Specialty Hospital’s private patient base; including a significant proportion of non-Jordanian medical tourism patients; provides research access to middle-to-upper-income Arabic-speaking patients from multiple Arab countries within an Amman private hospital setting; its JCI-accreditation and long track record of international pharmaceutical company research partnerships make it Jordan’s most sophisticated non-KHCC private research institution with established GCP documentation standards and pharmaceutical company relationship management experience. |
| 05 | Jordan Hospital | Amman | A major private hospital in Amman and one of Jordan’s most prominent medical tourism destinations; particularly for Iraqi, Libyan, and Yemeni patients seeking cardiac, oncology, and specialist care; with Phase II–III commercial research activity across cardiovascular, oncology, and internal medicine; Jordan Hospital’s cardiac surgery and cardiology departments are among the most active in Jordan and the broader Levant region, providing research access to a large cardiovascular patient population that includes both Jordanian nationals and the significant proportion of Arab medical tourists who choose Jordan Hospital for cardiac care; its established pharmaceutical company research relationships and experienced research coordination team sustain an active commercial trial portfolio complementary to the public and military hospital research networks. |
| 06 | Islamic Hospital | Amman | One of Amman’s largest and most historically established private hospitals; operated under Islamic charitable trust foundations reflecting Jordan’s strong tradition of faith-based healthcare; with Phase II–III commercial research activity across internal medicine, cardiovascular, diabetes, and oncology; Islamic Hospital’s large patient volume; serving Amman’s diverse urban population across a wide socioeconomic range; provides research access to the middle and lower-income Jordanian and Palestinian-origin patient demographic whose disease burden (high T2D, hypertension, obesity rates at lower household income levels) creates large treatment-naïve metabolic disease enrollment pools; an important institutional complement to the premium private hospitals for sponsors designing Jordan multi-site Phase III programs requiring patient coverage across the full Amman socioeconomic spectrum. |
| 07 | Prince Hamzah Hospital | Amman | A major Ministry of Health general hospital in Amman and one of Jordan’s most important public sector research sites; with Phase II–III commercial trial activity across internal medicine, cardiovascular, endocrinology, and infectious disease; Prince Hamzah Hospital’s MOH affiliation provides research access to Jordan’s public health insurance-covered population, including the large lower-income urban Jordanian and Syrian refugee-adjacent communities in Amman’s eastern districts; its infectious disease department has been active in refugee health research; including cutaneous leishmaniasis, hepatitis C, and conflict-related NCD management studies; reflecting the hospital’s geographic proximity to Amman’s largest concentrations of Syrian refugee urban settlers; an important public-sector research site for sponsors whose programs target the lower-income Jordanian and refugee-adjacent patient populations that private hospitals do not systematically enrol. |
| 08 | Al-Bashir Hospital | Amman | Jordan’s largest public general hospital; the Ministry of Health’s primary referral hospital in Amman, serving as the national referral centre for Jordan’s public health system; with Phase II–III research activity across infectious disease, cardiovascular, haematology, and internal medicine; Al-Bashir Hospital’s status as Jordan’s highest-volume public hospital creates research access to the largest and most socioeconomically diverse patient catchment in Amman; including significant refugee and Palestinian-origin patient populations; whose disease burden and treatment-naïve status reflect the full epidemiological complexity of Jordan’s rapidly urbanising, NCD-transitioning society; its haematology department has been particularly active in thalassaemia management and blood disorder research reflecting the elevated haemoglobin disorder prevalence in Jordan’s Levantine Mediterranean-ancestry population. |
| 09 | Istishari Hospital | Amman | A well-established private hospital in Amman’s Abdoun district; one of the capital’s most upscale and internationally oriented residential areas; with Phase II–III commercial trial activity across oncology, cardiovascular, and internal medicine; Istishari Hospital’s patient catchment from Amman’s professional and diplomatic community; including a significant proportion of Gulf expatriate residents, international NGO and UN staff families, and upper-income Jordanian and Palestinian-origin professionals; creates a research population whose health literacy, English proficiency, and trial compliance expectations reflect an international middle-class demographic; an important private hospital complement for sponsors designing Jordan Phase III programs requiring patient coverage across the full range of Amman’s socioeconomic and demographic diversity. |
| 10 | King Abdullah University Hospital (JUST) | Irbid | The academic teaching hospital of Jordan University of Science and Technology (JUST); Jordan’s largest technical and scientific university, located in Irbid in northern Jordan; and the most research-active institution in the north of the country; Phase II–III activity across oncology, cardiovascular, diabetes, and infectious disease; King Abdullah University Hospital’s position in Irbid; Jordan’s second-largest city (~350,000 population, in the northern highlands near the Syrian border); provides research access to a patient demographic that includes large concentrations of Syrian refugees in Irbid governorate (one of Jordan’s highest per-capita refugee hosting rates) alongside the Jordanian and Palestinian-origin urban population; JUST’s strong research tradition and international academic partnerships make it the primary academic research anchor for northern Jordan’s growing trial activity and the primary institutional partner for Syrian refugee health research. |
| 11 | Princess Basma Teaching Hospital | Irbid | A Ministry of Health teaching hospital in Irbid serving as the public sector research anchor for northern Jordan; providing healthcare to Irbid governorate’s large Jordanian, Palestinian, and Syrian refugee population; with Phase II–III research activity across maternal-fetal medicine, paediatrics, internal medicine, and infectious disease; Princess Basma Teaching Hospital’s proximity to Jordan’s highest Syrian refugee concentrations; particularly in Irbid city and Mafraq governorate; makes it an important institutional site for refugee health research programmes: mental health intervention trials, conflict-related NCD disruption studies, and infectious disease programs (cutaneous leishmaniasis, hepatitis) in a displaced population require a functioning healthcare facility adjacent to the refugee community, and Princess Basma fulfils this role for northern Jordan’s research programs. |
| 12 | Prince Hashem Military Hospital | Zarqa | The Royal Medical Services’ primary hospital in Zarqa; Jordan’s second-largest city (~500,000 population) and a heavily industrial, predominantly Palestinian-origin urban centre northeast of Amman; providing military healthcare to RMS beneficiaries in the greater Zarqa-Amman corridor while also serving as a research site for internal medicine, cardiovascular, and metabolic disease programs; Prince Hashem Military Hospital’s Zarqa location provides research access to a demographically distinct patient population from Amman’s hospital catchments; Zarqa’s predominantly lower-income Palestinian-Jordanian industrial working class carries specific cardiovascular, diabetes, and occupational health disease profiles relevant to sponsors designing Jordan Phase III programs with geographic patient coverage beyond the Amman metropolitan area; an important RMS network complement to King Hussein Medical Center’s Amman-centric military patient base. |
The Arab world’s most internationally recognised comprehensive cancer centre; JCI-accredited, a WHO Collaborating Centre for Cancer Control, and a member of the Organisation of European Cancer Institutes (OECI); offering the full spectrum of oncology services (radiation, medical, surgical, paediatric oncology, bone marrow transplantation, haematological malignancies) to a patient population drawn from 15+ Arab and African countries; Phase I–IV clinical trial portfolio with active partnerships with MD Anderson Cancer Center, St. Jude Children’s Research Hospital, and EORTC; KHCC’s dedicated clinical research department, GCP-compliant IRB, and internationally published investigator community create the Arab world’s most credentialed oncology trial execution environment; the multi-national medical tourism patient catchment makes KHCC the only institution in the Arab world where a Phase II–III oncology trial simultaneously accesses Jordanian, Iraqi, Yemeni, Libyan, Palestinian, Syrian, and North African Arabic-speaking cancer patients within a single regulatory submission.
Jordan’s primary public academic medical centre; affiliated with the University of Jordan (UJ) School of Medicine, the country’s oldest and largest medical school; and a significant Phase II–IV commercial research site across internal medicine, cardiovascular, endocrinology (Type 2 diabetes), oncology, nephrology, and neurology; Jordan University Hospital’s academic connection to UJ’s medical school produces the national investigator pipeline for Jordan’s public hospital research network and maintains active international academic partnerships through which multinational Phase II–III commercial programmes activate Jordanian sites; its large public hospital patient catchment; serving Amman’s diverse urban and suburban population including significant Palestinian-origin and Syrian refugee communities; creates research access to the Levantine Arab demographic breadth that defines Jordan’s urban patient profile.
The flagship hospital of Jordan’s Royal Medical Services (RMS); the Armed Forces’ comprehensive healthcare network serving military personnel, veterans, and their families across Jordan; and one of the Kingdom’s most research-active tertiary institutions; Phase II–IV commercial trial activity across cardiovascular (one of Jordan’s most active cardiac surgery and interventional cardiology programmes), oncology, haematology, internal medicine, and emergency medicine; King Hussein Medical Center’s RMS affiliation provides structured patient access to Jordan’s large military and veterans community; a population with distinct demographic characteristics and healthcare engagement patterns complementary to the civilian hospital networks; and its comprehensive cardiac programme makes it a key site for cardiovascular Phase II–III programs requiring Jordanian military and civilian patient coverage.
One of Amman’s most internationally connected and research-active private hospitals; a major medical tourism destination in its own right, attracting patients from Gulf countries, Iraq, Libya, and Yemen for specialist care; with Phase II–IV commercial trial activity across oncology, cardiovascular, neurology, and internal medicine; Specialty Hospital’s private patient base; including a significant proportion of non-Jordanian medical tourism patients; provides research access to middle-to-upper-income Arabic-speaking patients from multiple Arab countries within an Amman private hospital setting; its JCI-accreditation and long track record of international pharmaceutical company research partnerships make it Jordan’s most sophisticated non-KHCC private research institution with established GCP documentation standards and pharmaceutical company relationship management experience.
A major private hospital in Amman and one of Jordan’s most prominent medical tourism destinations; particularly for Iraqi, Libyan, and Yemeni patients seeking cardiac, oncology, and specialist care; with Phase II–III commercial research activity across cardiovascular, oncology, and internal medicine; Jordan Hospital’s cardiac surgery and cardiology departments are among the most active in Jordan and the broader Levant region, providing research access to a large cardiovascular patient population that includes both Jordanian nationals and the significant proportion of Arab medical tourists who choose Jordan Hospital for cardiac care; its established pharmaceutical company research relationships and experienced research coordination team sustain an active commercial trial portfolio complementary to the public and military hospital research networks.
One of Amman’s largest and most historically established private hospitals; operated under Islamic charitable trust foundations reflecting Jordan’s strong tradition of faith-based healthcare; with Phase II–III commercial research activity across internal medicine, cardiovascular, diabetes, and oncology; Islamic Hospital’s large patient volume; serving Amman’s diverse urban population across a wide socioeconomic range; provides research access to the middle and lower-income Jordanian and Palestinian-origin patient demographic whose disease burden (high T2D, hypertension, obesity rates at lower household income levels) creates large treatment-naïve metabolic disease enrollment pools; an important institutional complement to the premium private hospitals for sponsors designing Jordan multi-site Phase III programs requiring patient coverage across the full Amman socioeconomic spectrum.
A major Ministry of Health general hospital in Amman and one of Jordan’s most important public sector research sites; with Phase II–III commercial trial activity across internal medicine, cardiovascular, endocrinology, and infectious disease; Prince Hamzah Hospital’s MOH affiliation provides research access to Jordan’s public health insurance-covered population, including the large lower-income urban Jordanian and Syrian refugee-adjacent communities in Amman’s eastern districts; its infectious disease department has been active in refugee health research; including cutaneous leishmaniasis, hepatitis C, and conflict-related NCD management studies; reflecting the hospital’s geographic proximity to Amman’s largest concentrations of Syrian refugee urban settlers; an important public-sector research site for sponsors whose programs target the lower-income Jordanian and refugee-adjacent patient populations that private hospitals do not systematically enrol.
Jordan’s largest public general hospital; the Ministry of Health’s primary referral hospital in Amman, serving as the national referral centre for Jordan’s public health system; with Phase II–III research activity across infectious disease, cardiovascular, haematology, and internal medicine; Al-Bashir Hospital’s status as Jordan’s highest-volume public hospital creates research access to the largest and most socioeconomically diverse patient catchment in Amman; including significant refugee and Palestinian-origin patient populations; whose disease burden and treatment-naïve status reflect the full epidemiological complexity of Jordan’s rapidly urbanising, NCD-transitioning society; its haematology department has been particularly active in thalassaemia management and blood disorder research reflecting the elevated haemoglobin disorder prevalence in Jordan’s Levantine Mediterranean-ancestry population.
A well-established private hospital in Amman’s Abdoun district; one of the capital’s most upscale and internationally oriented residential areas; with Phase II–III commercial trial activity across oncology, cardiovascular, and internal medicine; Istishari Hospital’s patient catchment from Amman’s professional and diplomatic community; including a significant proportion of Gulf expatriate residents, international NGO and UN staff families, and upper-income Jordanian and Palestinian-origin professionals; creates a research population whose health literacy, English proficiency, and trial compliance expectations reflect an international middle-class demographic; an important private hospital complement for sponsors designing Jordan Phase III programs requiring patient coverage across the full range of Amman’s socioeconomic and demographic diversity.
The academic teaching hospital of Jordan University of Science and Technology (JUST); Jordan’s largest technical and scientific university, located in Irbid in northern Jordan; and the most research-active institution in the north of the country; Phase II–III activity across oncology, cardiovascular, diabetes, and infectious disease; King Abdullah University Hospital’s position in Irbid; Jordan’s second-largest city (~350,000 population, in the northern highlands near the Syrian border); provides research access to a patient demographic that includes large concentrations of Syrian refugees in Irbid governorate (one of Jordan’s highest per-capita refugee hosting rates) alongside the Jordanian and Palestinian-origin urban population; JUST’s strong research tradition and international academic partnerships make it the primary academic research anchor for northern Jordan’s growing trial activity and the primary institutional partner for Syrian refugee health research.
A Ministry of Health teaching hospital in Irbid serving as the public sector research anchor for northern Jordan; providing healthcare to Irbid governorate’s large Jordanian, Palestinian, and Syrian refugee population; with Phase II–III research activity across maternal-fetal medicine, paediatrics, internal medicine, and infectious disease; Princess Basma Teaching Hospital’s proximity to Jordan’s highest Syrian refugee concentrations; particularly in Irbid city and Mafraq governorate; makes it an important institutional site for refugee health research programmes: mental health intervention trials, conflict-related NCD disruption studies, and infectious disease programs (cutaneous leishmaniasis, hepatitis) in a displaced population require a functioning healthcare facility adjacent to the refugee community, and Princess Basma fulfils this role for northern Jordan’s research programs.
The Royal Medical Services’ primary hospital in Zarqa; Jordan’s second-largest city (~500,000 population) and a heavily industrial, predominantly Palestinian-origin urban centre northeast of Amman; providing military healthcare to RMS beneficiaries in the greater Zarqa-Amman corridor while also serving as a research site for internal medicine, cardiovascular, and metabolic disease programs; Prince Hashem Military Hospital’s Zarqa location provides research access to a demographically distinct patient population from Amman’s hospital catchments; Zarqa’s predominantly lower-income Palestinian-Jordanian industrial working class carries specific cardiovascular, diabetes, and occupational health disease profiles relevant to sponsors designing Jordan Phase III programs with geographic patient coverage beyond the Amman metropolitan area; an important RMS network complement to King Hussein Medical Center’s Amman-centric military patient base.
Jordan’s national food and drug regulatory authority; one of the Arab world’s most respected pharmaceutical regulatory agencies, recognised as a reference regulatory authority by multiple Arab League member states; governing pharmaceutical product registration, clinical trial authorisation, and pharmacovigilance under WHO GCP and ICH GCP E6(R2)-aligned regulations; JFDA’s bilateral MOU with the US FDA and cooperation agreement with the EMA provide the international regulatory alignment that underpins international sponsor confidence in JFDA-approved clinical trial data; clinical trial applications are reviewed primarily in English, and JFDA’s institutional regulatory capacity has been progressively strengthened through WHO and FDA technical assistance programmes.
Jordan’s national health policy coordination and research oversight body; coordinating between the Ministry of Health, Royal Medical Services, university hospitals, and private sector healthcare institutions; and providing the strategic health research policy framework within which JFDA’s clinical trial regulatory function operates; HHC’s national health research priorities; which explicitly include cancer, cardiovascular disease, diabetes, mental health, and refugee health; align closely with Jordan’s most commercially active research areas and reflect the evidence base generated by KHCC, Jordan University Hospital, and the JUST academic research network.
Jordan’s Ministry of Health; operating the national public hospital network (Prince Hamzah Hospital, Al-Bashir Hospital, Princess Basma Hospital, and regional hospitals across Jordan’s 12 governorates) and providing subsidised healthcare to Jordanian nationals and refugees through agreements with the UNHCR and donor-funded programmes; the MOH’s public hospital network provides the institutional research infrastructure for studies targeting Jordan’s lower-income and refugee-adjacent patient populations; complementing KHCC’s cancer-specialist and private hospitals’ middle-class catchments; and its national disease surveillance data provides the epidemiological baseline for commercial trial feasibility assessments across Jordan’s diverse geographic and demographic patient landscape.
The Arab world’s most internationally distinguished cancer research institution; JCI-accredited, WHO Collaborating Centre for Cancer Control, OECI member; whose clinical research department manages Jordan’s most active Phase I–IV oncology trial portfolio in partnership with MD Anderson Cancer Center, St. Jude Children’s Research Hospital, EORTC, and major multinational pharmaceutical companies; KHCC’s research programme is the primary institutional driver of Jordan’s growing international oncology research reputation and the most important single institutional partner for any sponsor entering the Jordanian oncology trial market; its biobank, molecular diagnostic laboratory, and dedicated IRB provide the translational research and ethics governance infrastructure that commercial Phase II–III oncology trials require.
Jordan’s oldest and largest medical school; affiliated with Jordan University Hospital and producing the primary national investigator pipeline for the public hospital research network; with active academic research programmes in cardiovascular medicine, endocrinology (diabetes research), infectious disease, and pharmacology; UJ School of Medicine’s international academic partnerships; with US, UK, European, and Gulf universities; create the cross-border academic relationships through which multinational commercial Phase II–III programmes access the Jordanian academic investigator community and UJ-affiliated public hospital patient populations; its Master’s and PhD-level biomedical research programmes train the next generation of Jordanian GCP-qualified clinical investigators.
Jordan’s largest technical and scientific university; based in Irbid in northern Jordan; whose Faculty of Medicine and affiliated King Abdullah University Hospital provide the primary academic medical research infrastructure for northern Jordan; JUST’s research programmes in infectious disease, refugee health, pharmacogenomics, and epidemiology reflect the specific disease burden and demographic challenges of northern Jordan’s high Syrian refugee concentration; JUST’s active international research partnerships; including with WHO, UNHCR, and international academic institutions conducting refugee health research; make it the primary academic partner for sponsors designing clinical research programs in Jordan’s Syrian refugee populations.
Jordan’s national oncology professional society; representing Jordanian oncologists, haematologists, and cancer researchers across KHCC, university hospitals, military hospitals, and private oncology centres; and the primary coordinating body for oncology clinical trial network development, investigator training, and international oncology research collaboration in Jordan; JOS’s active engagement with ESMO, ASCO, and EORTC creates the international oncology network connections through which Jordan’s investigators access multinational Phase III cooperative group programmes and through which international sponsors identify the Jordanian investigator community for commercial oncology trial partnerships; JOS annual meetings and clinical trial workshops provide the principal platform for sponsor-investigator engagement across Jordan’s dispersed oncology research institutions.
Global CRO with Jordan operations managed through its MENA regional network; supporting Phase II–IV programs across oncology (KHCC platform and Jordanian oncology network), metabolic disease, cardiovascular, and mental health indications; JFDA regulatory submission expertise and institutional IRB ethics application support across KHCC, Jordan University Hospital, King Hussein Medical Center, and Amman’s private hospital cluster; JOD financial management with USD equivalence simplifying IQVIA’s Jordan operations; MENA regional coordination integrating Jordanian sites with Saudi Arabia, UAE, Egypt, Lebanon, and Morocco within integrated Arab-market Phase III programs for sponsors building comprehensive MENA regional clinical development portfolios.
International CRO with Jordanian operations supporting Phase II–IV oncology, cardiovascular, metabolic disease, and mental health programs; established investigator relationships across KHCC’s clinical research department, Jordan University Hospital, and Specialty Hospital; specialist oncology and haematology trial management reflecting Jordan’s KHCC-anchored oncology research profile; JFDA regulatory strategy for sponsors using Jordan as the Arab oncology anchor of MENA multi-country Phase III programs; medical tourism patient enrollment coordination at KHCC for sponsors whose protocols can enrol Arabic-speaking patients of multiple Arab national origins under the Jordanian regulatory framework.
Global CRO with Jordan operations providing Phase II–III trial management and JFDA regulatory strategy across oncology, cardiovascular, metabolic disease, and mental health indications; established site networks across Amman’s KHCC, Jordan University Hospital, King Hussein Medical Center, and major private hospital research cluster alongside King Abdullah University Hospital in Irbid; biostatistics and data management for Jordan-site trials with multi-nationality Arab patient sub-group analysis across Jordanian, Palestinian, Iraqi, Yemeni, and Syrian ancestry patient populations enrolled through KHCC’s medical tourism catchment; MENA regional programme coordination spanning Jordan, Egypt, Lebanon, and Morocco.
Jordan’s pharmaceutical industry association; representing both multinational research pharmaceutical companies and Jordan’s significant domestic generic pharmaceutical manufacturing sector (Jordan is one of the Arab world’s most productive pharmaceutical manufacturers, exporting to Gulf countries, Iraq, and Africa); and the primary industry interface with JFDA for pharmaceutical regulatory policy, clinical trial legislation, and MENA pharmaceutical harmonisation; JAPM’s active engagement with JFDA’s clinical trial regulatory modernisation; including alignment with WHO and ICH GCP standards; has been a consistent driver of the regulatory improvements that have made Jordan increasingly attractive as an Arab-world clinical research destination; Jordan’s pharmaceutical manufacturing tradition also creates a sophisticated local pharmaceutical regulatory intelligence community that benefits international sponsors navigating JFDA’s approval processes.
Jordan is the Arab world’s oncology research capital and the Middle East’s most cost-effective high-quality research destination for sponsors who need Arabic-speaking patient populations without Gulf pricing. King Hussein Cancer Center is the irreplaceable institutional anchor: the only JCI-accredited, WHO Collaborating Centre for Cancer, OECI-member oncology institution in the Arab world that simultaneously draws patients from Iraq, Yemen, Libya, Sudan, Palestine, Syria, and 10+ other Arab countries; creating a multi-national Arabic-speaking oncology patient pool under a single JFDA regulatory submission that sponsors cannot access anywhere else without activating multiple national filings across unstable or low-infrastructure Arab research markets. The medical tourism argument is Jordan’s most distinctive commercial asset: no other research market in this series operates at a scale where one institution’s patient catchment organically spans 15+ nationalities; in Jordan’s case, the political instability of Iraq, Yemen, Libya, and Syria has redirected their cancer patients to Amman, where KHCC’s quality provides the care their home-country systems cannot, and where a JFDA-approved Phase II trial simultaneously enrolls cancer patients from five Arab ancestries. The JOD/USD peg since 1995 eliminates the currency management overhead that complicates every other non-Gulf MENA research budget; at a cost structure substantially below Saudi Arabia, UAE, or Israel, making Jordan the most cost-efficient MENA oncology research hub for sponsors whose programs do not require the ICH membership status of Israel or the Gulf’s T2D patient volumes. The Syrian refugee argument is Jordan’s most globally distinctive emerging research frontier: 1.3–1.5 million displaced Syrians; the world’s largest per-capita displaced population within a stable, research-capable country; create a conflict-affected health research platform for mental health, PTSD, chronic disease management disruption, and infectious disease programs that no other functioning research jurisdiction can replicate. Jordan is not competing with Israel, Saudi Arabia, or the UAE for the same sponsor wallet; it occupies a specific and irreplaceable niche as the Arab world’s oncology reference, multi-Arab patient hub, and refugee health research platform at the region’s most competitive cost structure.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.